Bullish indicating open at $55-$60, IPO prices at $37
Applied DNA Sciences, Inc. (NASDAQ:APDN), currently trading at $5.04 with a market capitalization of $2.58 million, announced Monday that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The company received written notice from The Nasdaq Stock Market that it now meets the requirements of Nasdaq Listing Rule 5550(a)(2), which mandates that listed companies maintain a minimum bid price of $1.00 per share. This development comes amid challenging market conditions, with InvestingPro data showing the stock has experienced significant price volatility, declining 97% over the past six months.
As a result of regaining compliance, the hearing before the Nasdaq Hearings Panel that had been scheduled for July 15, 2025, has been cancelled. Applied DNA Sciences’ securities will continue to be listed and traded on the Nasdaq Capital Market.
The information is based on a press release statement included in the company’s recent filing with the Securities and Exchange Commission.
In other recent news, Applied DNA Sciences has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This follows the company’s earlier notification of non-compliance with the $1.00 minimum bid price rule, which led to a 1-for-15 reverse stock split. The company has also announced a strategic restructuring, including a 27% workforce reduction and the closure of its Applied DNA Clinical Labs business, to focus on its synthetic DNA manufacturing division, LineaRx. This move is projected to reduce annual payroll costs by 23%.
Furthermore, Applied DNA Sciences has secured a U.S.-based supply chain for key materials used in its LineaDNA and LineaIVT platforms, aligning with industry trends toward reshoring biopharmaceutical manufacturing. The company has appointed Judy Murrah as the new Chairperson and CEO, succeeding Dr. James A. Hayward. Murrah brings extensive leadership experience and will lead the executive management team. These developments reflect the company’s efforts to streamline operations and focus on growth opportunities in the genetic medicines market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.